SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form DEF 14A - Other definitive proxy statements:
SEC Accession No. 0000950170-24-047673
Filing Date
2024-04-24
Accepted
2024-04-24 16:57:59
Documents
21
Period of Report
2024-04-24

Document Format Files

Seq Description Document Type Size
1 DEF 14A ovid-20240424.htm   iXBRL DEF 14A 876646
2 GRAPHIC img44212337_0.jpg GRAPHIC 242993
3 GRAPHIC img44212337_1.jpg GRAPHIC 16469
4 GRAPHIC img44212337_2.jpg GRAPHIC 92038
5 GRAPHIC img44212337_3.jpg GRAPHIC 87075
6 GRAPHIC img44212337_4.jpg GRAPHIC 88870
7 GRAPHIC img44212337_5.jpg GRAPHIC 21957
8 GRAPHIC img44212337_6.jpg GRAPHIC 21220
9 GRAPHIC img44212337_7.jpg GRAPHIC 925675
10 GRAPHIC img44212337_8.jpg GRAPHIC 767719
  Complete submission text file 0000950170-24-047673.txt   6621737

Data Files

Seq Description Document Type Size
11 XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT ovid-20240424.xsd EX-101.SCH 29276
24 EXTRACTED XBRL INSTANCE DOCUMENT ovid-20240424_htm.xml XML 119839
Mailing Address 441 NINTH AVENUE, 14TH FLOOR NEW YORK NY 10001
Business Address 441 NINTH AVENUE, 14TH FLOOR NEW YORK NY 10001 212-776-4381
Ovid Therapeutics Inc. (Filer) CIK: 0001636651 (see all company filings)

IRS No.: 465270895 | State of Incorp.: DE | Fiscal Year End: 1231
Type: DEF 14A | Act: 34 | File No.: 001-38085 | Film No.: 24871330
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)